Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553710 | 0.90 | ALDH1A1 (0.43) | HTR2AHTR2CHTR2BSCDCHKA | |
| SCHEMBL11893058 | 0.84 | NOTUM (0.41) | HTR2AHTR2CHTR2BNOTUMSLC22A12 | |
| SCHEMBL9327726 | 0.80 | SLC22A12 (0.59) | NOTUMSLC22A12ACHENPY2RMEN1 | |
| SCHEMBL17112286 | 0.80 | HTR2C (0.39) | HTR2AHTR2CHTR2BSCDNOTUM | |
| SCHEMBL23349378 | 0.79 | RORC (0.39) | HTR2AHTR2CHTR2BNOTUM | |
| SCHEMBL18355814 | 0.78 | HTR2C (0.39) | HTR2AHTR2CHTR2BSCDNOTUM | |
| SCHEMBL23633824 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BSCDNOTUM | |
| SCHEMBL18361489 | 0.78 | HTR2C (0.39) | HTR2AHTR2CHTR2BSCDNOTUM | |
| SCHEMBL12683270 | 0.78 | DRD2 (0.50) | CHKADRD2DRD1DRD5DRD3 | |
| SCHEMBL15497457 | 0.77 | PRMT5 (0.36) | HTR2AHTR2CHTR2BCHKANISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015140133-A1 | PIPERIDINE-DIONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2686302-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | KALLYOPE, INC. | 2014-01-02 | — | — | US | disclosed |
| CN-103443080-A | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORP | 2013-12-11 | — | — | CN | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | HTR2A 641/4885HTR2C 664/4885HTR2B 1145/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | HTR2A 233/4885HTR2C 213/4885HTR2B 297/4885 |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | HTR2A 663/4885HTR2C 694/4885HTR2B 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.